Your browser doesn't support javascript.
loading
Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
Jackson, Ronald J; Worley, Matthew; Trivedi, Shubhanshi; Ranasinghe, Charani.
Afiliação
  • Jackson RJ; Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.
  • Worley M; Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.
  • Trivedi S; Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.
  • Ranasinghe C; Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia. Electronic address: Charani.Ranasinghe@anu.edu.au.
Vaccine ; 32(43): 5703-14, 2014 Sep 29.
Article em En | MEDLINE | ID: mdl-25151041
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Infecções por HIV / Vacinas contra a AIDS / Linfócitos T CD8-Positivos / Receptores de Interleucina-4 Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Infecções por HIV / Vacinas contra a AIDS / Linfócitos T CD8-Positivos / Receptores de Interleucina-4 Idioma: En Ano de publicação: 2014 Tipo de documento: Article